Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Phase 3negativeTNX-103Negative
AI Analysis
Summary
Tenax Therapeutics announced that TNX-103 failed to meet the primary endpoint of improvement in 6-minute walk distance versus placebo in the Phase 3 LEVEL clinical trial for patients with pulmonary hypertension and heart failure with preserved ejection fraction.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo
Importance:8/10
Sentiment:
-0.90
Phase 3 failureTNX-103PH-HFpEFprimary endpoint missed6-minute walk distance
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on August 10, 2026 11:00 AM